The Leader in Data-Driven Medicine, SOPHiA GENETICS has announced the closing of a USD77 million funding round to speed up the democratization of Data-Driven Medicine. The funding round led by Generation Investment Management, a pioneer of sustainable investing. Incepted in Switzerland, SOPHiA GENETICS is now co-based in Lausanne and Boston. The company has a blend of expertise in life sciences and medical disciplines with mathematical capabilities in data computing.
Today, SOPHiA GENETICS’ universal platform, SOPHiA AI, is used by over 850 healthcare centers across 77 nations and has already aided the diagnosis of more than 300,000 patients. The company’s platform allows healthcare personnel to make sense of compound genomic and radiomic data through enhanced analysis with the aim of better diagnose and treat patients, both for oncology and hereditary disorders. SOPHiA GENETICS, with this new funding round, has now hoisted a sum of USD140 million, will enable the company to further cultivate the global community healthcare centers utilizing its technology. The company, additionally, will keep on furthering talent to bolster its rapid mounting presence in the US.
CEO and Founder of SOPHiA GENETICS, Dr. Jurgi Camblong stated that since the company founded, its goal has been to assist make the global healthcare system more sustainable. By supporting clinical researchers embrace their expertise and work together as communities; patients across the globe can get equivalent access to better care. Camblong further said that Generation Investment Management and SOPHiA GENETICS are steered by identical belief. The company, with the support of Generation Investment Management, will allow the more adoption of Data-Driven Medicine technology in the healthcare sector for the advantage of patients globally.